Enanta secures FDA fast track designation for EDP-323 to treat RSV
Pharmaceutical Technology
APRIL 7, 2023
Enanta Pharmaceuticals has secured the US Food and Drug Administration’s (FDA) fast track designation for EDP-323 to treat respiratory syncytial virus (RSV). In vitro data of EDP-323 showed a significant reduction in RSV replication with picomolar potency in primary human bronchial epithelial cells against RSV A and B.
Let's personalize your content